Evidence map›Paper›PMID 41408661›Full record

ArticleActa neuropathologica communications2025

Disordered DNA methylation leads to targetable transcriptional plasticity in ATRT.

Ashley R Tetens, Tyler R Findlay, Jordyn Craig-Schwartz, Athanasia Liapodimitri, Oscar Camacho, Kegan O Skalitzky, Adrian Idrizi, Rakel Tryggvadottir, Kayleigh Lunsford, Eric H Raabe and 1 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ashley R TetensCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Tyler R FindlayPediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Jordyn Craig-SchwartzCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Athanasia LiapodimitriCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Oscar CamachoCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Kegan O SkalitzkyCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Adrian IdriziCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Rakel TryggvadottirCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Kayleigh LunsfordCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Eric H RaabePediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Michael A KoldobskiyCenter for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. mak@jhmi.edu.

Funding

Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
Hyundai Hope On Wheels Hope Scholar GrantNIGMS NIH HHS T32 GM136577Rally Foundation Career Development Award
6 · The paper itself

Abstract

Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive but genetically simple pediatric central nervous system tumor, defined by biallelic inactivation of the chromatin regulator SMARCB1 with remarkably few other cooperating mutations. Despite its genetic homogeneity, ATRT exhibits profound clinical and epigenetic heterogeneity, with three major subgroups (ATRT-TYR, ATRT-MYC, and ATRT-SHH) defined by DNA methylation and transcriptional signatures. Beyond these subgroup-defining features, we aimed to investigate epigenetic variability within tumors by applying whole-genome bisulfite sequencing and probabilistic modeling to quantify stochastic DNA methylation in primary ATRT samples encompassing all three subgroups. We show that ATRT exhibits a destabilized and increasingly stochastic methylome. While ATRT global methylation patterns diverge according to subgroup, some methylation perturbations, such as hypermethylation and increased methylation entropy over bivalent promoters, are consistent across subgroups. We find that methylation stochasticity alterations map onto potential drivers of ATRT, such as LIN28a, the HOXD cluster for ATRT-MYC, and OTX2 for ATRT-TYR, and identify actionable targets, such as hypermethylation of the tumor suppressor CDKN2a across all subgroups. We investigate the sensitivity of the aberrant DNA methylation landscape of ATRT to pharmacologic DNA methyltransferase inhibition (DNMTi) and histone deacetylase inhibition (HDACi). We show that decitabine leads to profound demethylation of patient-derived ATRT cell lines, including reversal of hypermethylation at bivalent promoters and the CDKN2a locus. The addition of HDACi leads to dramatic gene expression changes, including upregulation of innate immune signaling pathways, such as STING/interferon signaling, genes under the regulation of bivalent promoters, and reactivation of the tumor suppressor CDKN2A. The combination of DNMTi and HDACi synergistically reduces cell viability. Taken together, we show that ATRT has a highly stochastic methylome sensitive to epigenetic manipulation.

Indexed as

DNA MethylationRhabdoid TumorCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansSMARCB1 ProteinHistone Deacetylase InhibitorsSMARCB1 ProteinSMARCB1 protein, human

Identifiers

PMID41408661
PMCPMC12821819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.